Stoke Therapeutics Inc

Stoke Therapeutics insider sales reveal routine RSU‑driven moves, not a sign of distress, amid a volatile 52‑week low and bullish analyst outlook.

Insider trades reveal a shift in Stoke Therapeutics’ ownership; executives are buying and selling amid a Phase‑3 trial, signaling cautious confidence and liquidity planning.

Stoke Therapeutics insider buying spree signals executive confidence in its antisense platform—read why this could boost investor prospects.